TITLE

Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa

AUTHOR(S)
Haberer, Jessica E.; Baeten, Jared M.; Campbell, James; Wangisi, Jonathan; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Psaros, Christina; Safren, Steven A.; Ware, Norma C.; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Celum, Connie; Bangsberg, David R.
PUB. DATE
September 2013
SOURCE
PLoS Medicine;Sep2013, Vol. 10 Issue 9, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: Jessica Haberer and colleagues investigate the association between high adherence to antiretroviral pre-exposure prophylaxis and HIV transmission in a substudy of serodiscordant couples participating in a clinical trial. Please see later in the article for the Editors' Summary
ACCESSION #
90530090

 

Related Articles

  • Who's prepared to make PrEP work? Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p5 

    Tenofovir/emtricitabine (TDF/FTC) won FDA approval for preexposure prophylaxis (PrEP) after three placebo-controlled trials demonstrated that once-daily TDF/FTC lowers HIV acquisition risk in gay and bisexual men and heterosexual women and men. In the one trial that found no HIV protection with...

  • Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings. Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D...

  • No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. Marcus, Julia L.; Glidden, David V.; Mayer, Kenneth H.; Liu, Albert Y.; Buchbinder, Susan P.; Amico, K. Rivet; McMahan, Vanessa; Kallas, Esper Georges; Montoya-Herrera, Orlando; Pilotto, Jose; Grant, Robert M. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We...

  • Letter from the Executive Director. Caldwell, Katy // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p3 

    An introduction is presented in which the author discusses various reports within the issue including one about adherence to Truvada as pre-exposure prophylaxis (PrEP), another one about a PrEP trial in gay and bisexual men and transgender women, and one about integrating PrEP into practice.

  • Virological efficacy of abacavir: systematic review and meta-analysis. Cruciani, Mario; Mengoli, Carlo; Malena, Marina; Serpelloni, Giovanni; Parisi, Saverio G.; Moyle, Graeme; Bosco, Oliviero // Journal of Antimicrobial Chemotherapy (JAC);Dec2014, Vol. 69 Issue 12, p3169 

    Objectives The efficacy of abacavir/lamivudine has been reported to be inferior to tenofovir/emtricitabine. Several randomized clinical trials (RCTs) investigated the effectiveness and safety of abacavir/lamivudine and tenofovir/emtricitabine combined antiretroviral treatment (cART) and we have...

  • Emtricitabini ettenofoviri compressi: Emtricitabine and tenofovir tablets.  // WHO Drug Information;2010, Vol. 24 Issue 4, p330 

    The article reports on several chemical tests that the World Health Organization conducted in 2010 on the combination antiretroviral treatment which features the drugs Emtricitabine and tenofovir to evaluate the drugs' safety and efficacy. A discussion of recommendations which the organizations...

  • Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. Juday, Timothy; Correll, Todd; Anene, Ayanna; Broder, Michael S.; Ortendahl, Jesse; Bentley, Tanya // ClinicoEconomics & Outcomes Research;2013, Vol. 5, p437 

    Background: February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line...

  • Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study. Gupta, Samir K.; Shen, Changyu; Moe, Sharon M.; Kamendulis, Lisa M.; Goldman, Mitchell; Graham, Susan Marie; Dubé, Michael P. // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    Objective: Changes in endothelial function, measured as flow-mediated dilation (FMD) of the brachial artery, has not been systematically assessed beyond 6 months of initiation of antiretroviral therapy (ART) when drug-related effects might offset initial improvements with virologic control....

  • Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring. Fink, Douglas L; Bloch, Edward // International Journal of STD & AIDS;Oct2013, Vol. 24 Issue 10, p831 

    We present the first case report in the UK of acute liver failure caused by efavirenz therapy culminating in liver transplantation. A 26-year-old Zimbabwean woman commenced emtricitabine, tenofovir and efavirenz (Atripla) in December 2011. Her liver function tests at baseline and at 20 days...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics